Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03713424 · ClinicalTrials.gov registry record · Phase 2
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
A Phase 2 study of Tobacco Use Disorder, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03713424: Recruiting Phase 2 study of Tobacco Use Disorder, sponsored by University of Missouri-Columbia.
NCT03713424 is a Phase 2 study of Tobacco Use Disorder that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 30 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03713424, a Phase 2 study of Tobacco Use Disorder, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.
Primary Outcome
Biochemical smoking assessment (breath carbon monoxide) at each study visit.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Clavulanic Acid
Study Locations (1)
Missouri
- University of Missouri - Columbia - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
What NCT03713424 shows while recruiting
NCT03713424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03713424 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03713424 about?
NCT03713424 is a clinical study titled "An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction". This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.
What is the current status of trial NCT03713424?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-03-26. Estimated completion is 2026-08-31.
What conditions does trial NCT03713424 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT03713424?
The interventions under investigation include: Placebo oral capsule (DRUG), Clavulanic Acid (DRUG).
Who is sponsoring clinical trial NCT03713424?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03713424 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03713424's enrollment target sits among peer trials
30 61st of 70 higher than 9 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
-
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI